Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arvac
- Development stage
- Unknown
- Lead developer
- Laboratorio Pablo Cassará
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Arvac (also known as Arvac Cecilia Grierson) is a recombinant protein subunit vaccine developed in Argentina by **Laboratorio Pablo Cassará** in collaboration with the **National Scientific and Technical Research Council (CONICET)** and the **National University of San Martín (UNSAM)**. It is the first COVID-19 vaccine entirely developed and manufactured in Argentina. The vaccine utilizes the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen, produced using a yeast-based expression system (*Pichia pastoris*). It is formulated with an aluminum hydroxide adjuvant to enhance the immune response. Arvac was approved by the Argentine regulatory agency **ANMAT** in October 2023 as a booster dose for individuals aged 18 and older, with versions adapted to circulating variants such as Gamma and Omicron.
- Brand names
- Arvac
- Other names
- Arvac Cecilia GriersonARVAC-CG vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Arvac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arvac.